Chad
Tuberculosis profile
| High HIV burden |
Population  2012 12 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (0.98–4.1) 18 (7.9–33)
Mortality (HIV+TB only) 1.4 (1.2–1.7) 11 (9.6–14)
Prevalence  (includes HIV+TB) 28 (14–46) 221 (109–372)
Incidence  (includes HIV+TB) 19 (16–22) 151 (125–180)
Incidence (HIV+TB only) 4.1 (3.4–4.8) 33 (27–39)
Case detection, all forms (%) 56 (47–68)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 849 (39) Relapse 634 (75)
Smear-negative 3 357 (34) Treatment after failure 90 (11)
Smear-unknown / not done 1 452 (15) Treatment after default 125 (15)
Extrapulmonary 1 113 (11) Other 0 (0)
Other 180 (2)      
Total new 9 951   Total retreatment 849  
           
Other (history unknown) 0        
Total new and relapse 10 585   Total cases notified 10 800  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.1 1.7 1.5
Age < 15 119 370 244
Laboratories 2012
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 68   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 69  
Retreatment 60  
TB/HIV 2012 Number (%)
TB patients with known HIV status 4 766 (44)
HIV-positive TB patients 960 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 626 (65)
HIV-positive people screened for TB 960  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
160 (9–300) 160 (63–260)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) 1
% Funded domestically 74%
% Funded internationally 26%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data